In contrast, pharmacological agents such as GLP-1 receptor agonists, including semaglutide (Ozempic), have become widespread treatments for obesity and Type 2 Diabetes. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.